{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T01:12:35Z","timestamp":1784337155074,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.tips.2025.06.004","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T08:11:38Z","timestamp":1751703098000},"page":"922-923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nemolizumab (Nemluvio\u00ae) for prurigo nodularis"],"prefix":"10.1016","volume":"46","author":[{"given":"Svenja","family":"Royeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2025.06.004_bb0005","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/all.14791","article-title":"Interleukin-31: the \"itchy\" cytokine in inflammation and therapy","volume":"76","author":"Datsi","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.tips.2025.06.004_bb0010","article-title":"Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues","volume":"8","author":"Nemmer","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.tips.2025.06.004_bb0015","article-title":"Interleukin-31 as a clinical target for pruritus treatment","volume":"8","author":"Kabashima","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.tips.2025.06.004_bb0020","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.06.004_bb0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial","volume":"161","author":"St\u00e4nder","year":"2024","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.tips.2025.06.004_bb0030","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.06.004_bb0035","series-title":"Nemolizumab Elicits an Early and Rapid Itch Response in Prurigo Nodularis within 2 Days: A Post Hoc Analysis of OLYMPIA 1&2 Data","author":"St\u00e4nder","year":"2024"},{"key":"10.1016\/j.tips.2025.06.004_bb0040","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1074\/jbc.M109.049189","article-title":"Molecular dissection of human IL-31-mediated signal transduction through site-directed mutagenesis","volume":"285","author":"Le Saux","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2025.06.004_bb0045","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cytogfr.2008.08.003","article-title":"Structures and biological functions of IL-31 and IL-31 receptors","volume":"19","author":"Zhang","year":"2008","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.tips.2025.06.004_bb0050","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-022-01741-z","article-title":"Nemolizumab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725001221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725001221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:17:11Z","timestamp":1757031431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614725001221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0165614725001221"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2025.06.004","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nemolizumab (Nemluvio\u00ae) for prurigo nodularis","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2025.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}